Summary
Janssen Biotech Inc (Janssen), formerly Centocor Ortho Biotech Inc. is a subsidiary of Johnson & Johnson, pharmaceutical company that manufactures, develops, and markets prescription drugs in immunology, nephrology and oncology areas. The company offers products such as stelara ustekinumab, simponi aria golimumab, remicade infliximab, procrit epoetin alfa, m doxil doxorubicin HCl liposome injection and zytiga abiraterone acetate. Its products are used for the treatment of infections that include muscle aches, cough, shortness of breath, fever, sweats, blood in phlegm, weight loss and stomach pain. The company also provides medical information database and reimbursement resources. Janssen is headquartered in Horsham, Pennsylvania, the US.
Janssen Biotech Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 8
Janssen Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 9
Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 10
Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 11
Janssen Biotech Inc, Medical Devices Deals, 2010 to YTD 2016 13
Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 14
Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deal Details 19
Partnerships 19
Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 19
HitGen Enters into Agreement with Janssen Biotech 20
Innovative Targeting Solutions Enters into Research Agreement with Janssen Biotech 21
Philogen Enters into Co-Development Agreement with Janssen Biotech 22
Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 23
Amyris Enters into Research Agreement with Janssen Biotech 24
Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 25
Enterome Bioscience Enters into Research Agreement with Janssen Biotech 26
Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 27
Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 28
Janssen Biotech Enters into Agreement with HUB foundation 29
Janssen Biotech Enters into Agreement with Eureka Therapeutics 30
Nuevolution Enters into Discovery Agreement with Janssen Biotech 31
enGene Enters into Agreement with Janssen Biotech 32
OICR and Novera Therapeutics Enter into Co-Development Agreement with Janssen Biotech 33
UbiVac Enters into Agreement with Janssen Biotech 34
Protectimmun Enters into Research Agreement with Janssen Biotech And Imperial College 35
Nextera Enters into Research Agreement with Janssen Biotech 36
Janssen Biotech Enters into Research Agreement with Emulate 37
X-Chem Enters into Agreement with Janssen Biotech 38
Vectura Enters into Development and License Agreement with Janssen Biotech 39
Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA-Targeted Therapeutics 40
Atreca Enters into Research Agreement with Janssen Biotech 41
Weill Cornell Medical College Enters into Co-Development Agreement with Janssen Biotech and Johnson & Johnson Innovation 42
University of Texas MD Anderson Cancer Center Enters Into Co-Development Agreement With Johnson & Johnson Innovation And Janssen Biotech 43
Scholar Rock Enters Into Research Collaboration With Johnson & Johnson Innovation And Janssen Biotech 45
Capricor Enters Into Co-Development Agreement With Janssen For Cell Therapy For Cardiovascular Applications 47
Second Genome Enters Into Agreement With Janssen Biotech For Microbiome Drug Discovery 48
Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 50
Araxes Pharma Enters Into Drug Discovery Agreement With Janssen Biotech For Cancer 52
FORMA Therapeutics Enters Into Co-Development Agreement With Janssen Biotech 53
Molecular Partners Enters Into Research Agreement With Janssen Biotech 54
Topivert Enters into Drug Discovery Collaboration Agreement with RespiVert 55
Licensing Agreements 56
Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 56
Janssen Biotec Enters into Licensing Agreement with MacroGenics 57
Janssen Biotech Enters into Licensing agreement with Tesaro 59
Janssen Biotech Exercises Option for Licensing Agreement with X-Chem 60
ViaCyte Enters into Licensing Agreement with Janssen Biotech 61
Janssen Biotech Exercises Option for Licensing Agreement with Scholar Rock 62
Janssen Biotech to Enter into Licensing Agreement with Alligator Bioscience for ADC-1013 63
Poseida Therapeutics Enters into Licensing Agreement with Janssen Biotech 65
Poseida Therapeutics Enters into Licensing Agreement with Janssen 66
Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 67
Applied Molecular Transport Enters into Licensing Agreement with Janssen Biotech 68
MacroGenics Enters into Licensing Agreement with Janssen Biotech for MGD011 69
Vedanta Biosciences Enters into Licensing Agreement with Janssen Biotech 71
Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech 72
Geron Enters into Licensing Agreement with Janssen Biotech for Imetelstat 74
Modern Biosciences Enters into Licensing Agreement with Janssen Biotech 77
Transposagen BioPharma Enters into Licensing Agreement with Janssen Biotech 78
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 79
Aduro BioTech Enters into Exclusive Licensing Agreement with Janssen Biotech 80
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 81
Amunix Expands Licensing Agreement With Janssen For XTEN Technology 83
CSL Enters Into Licensing Agreement With Janssen For CSL-362 85
Genmab Expands Licensing Agreement With Janssen Biotech 87
Janssen Biotech Exercises Option for Licensing Agreement with OSE Immunotherapeutics 89
Amunix Exercises Option For Licensing Agreement With Janssen Biotech For XTEN Technology 90
Janssen Biotech Exercises Option For Licensing Agreement With Forma Therapeutics 91
Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 93
Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 94
Amunix Enters Into Licensing Agreement With Janssen Biotech For Proprietary XTEN Technology 95
Phenex Pharma Enters Into Licensing Agreement With Janssen Biotech For Retinoid-Acid Receptor-Related Orphan Receptor Gamma t Program 96
Janssen Biotech to Terminate Licensing Agreement with Astellas Pharma for ASP015K 98
Genmab Enters Into Licensing Agreement With Janssen Biotech For Daratumumab 100
ImmuNext Enters Into Licensing Agreement With Janssen Biotech 102
Genmab Enters Into Licensing Agreement With Janssen Biotech For DuoBody Technology 104
Phylogica Enters Into Licensing Agreement With Janssen Biotech For Phylomer Technology 105
Metamark Genetics Enters Into Licensing Agreement With Janssen Biotech 106
Janssen Biotech Enters Into Licensing Agreement With Pharmacyclics For PCI-32765 107
Topivert Enters into Licensing Agreement with RespiVert 109
AVEO Pharma Enters Into Licensing Agreement With Centocor Ortho Biotech 110
Horizon Discovery Enters Into Licensing Agreement With Centocor Ortho Biotech 112
Acquisition 113
Janssen Biotech Enters Into Option To Acquire Amphivena From Affirmed Therapeutics 113
Janssen Biotech To Acquire Vascular Pharma, Diabetes Drug Developer 115
Centocor Ortho Biotech Acquires RespiVert 116
Janssen Biotech Inc - Key Competitors 118
Key Employees 119
Locations And Subsidiaries 120
Head Office 120
Other Locations & Subsidiaries 120
Appendix 121
Methodology 121
About GlobalData 121
Contact Us 121
Disclaimer 121
List Of Tables
List of Tables
Janssen Biotech Inc, Pharmaceuticals & Healthcare, Key Facts 1
Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 8
Janssen Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 9
Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 10
Janssen Biotech Inc, Deals By Therapy Area, 2010 to YTD 2016 11
Janssen Biotech Inc, Medical Devices Deals, 2010 to YTD 2016 13
Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 14
Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 19
HitGen Enters into Agreement with Janssen Biotech 20
Innovative Targeting Solutions Enters into Research Agreement with Janssen Biotech 21
Philogen Enters into Co-Development Agreement with Janssen Biotech 22
Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 23
Amyris Enters into Research Agreement with Janssen Biotech 24
Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 25
Enterome Bioscience Enters into Research Agreement with Janssen Biotech 26
Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 27
Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 28
Janssen Biotech Enters into Agreement with HUB foundation 29
Janssen Biotech Enters into Agreement with Eureka Therapeutics 30
Nuevolution Enters into Discovery Agreement with Janssen Biotech 31
enGene Enters into Agreement with Janssen Biotech 32
OICR and Novera Therapeutics Enter into Co-Development Agreement with Janssen Biotech 33
UbiVac Enters into Agreement with Janssen Biotech 34
Protectimmun Enters into Research Agreement with Janssen Biotech And Imperial College 35
Nextera Enters into Research Agreement with Janssen Biotech 36
Janssen Biotech Enters into Research Agreement with Emulate 37
X-Chem Enters into Agreement with Janssen Biotech 38
Vectura Enters into Development and License Agreement with Janssen Biotech 39
Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA-Targeted Therapeutics 40
Atreca Enters into Research Agreement with Janssen Biotech 41
Weill Cornell Medical College Enters into Co-Development Agreement with Janssen Biotech and Johnson & Johnson Innovation 42
University of Texas MD Anderson Cancer Center Enters Into Co-Development Agreement With Johnson & Johnson Innovation And Janssen Biotech 43
Scholar Rock Enters Into Research Collaboration With Johnson & Johnson Innovation And Janssen Biotech 45
Capricor Enters Into Co-Development Agreement With Janssen For Cell Therapy For Cardiovascular Applications 47
Second Genome Enters Into Agreement With Janssen Biotech For Microbiome Drug Discovery 48
Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 50
Araxes Pharma Enters Into Drug Discovery Agreement With Janssen Biotech For Cancer 52
FORMA Therapeutics Enters Into Co-Development Agreement With Janssen Biotech 53
Molecular Partners Enters Into Research Agreement With Janssen Biotech 54
Topivert Enters into Drug Discovery Collaboration Agreement with RespiVert 55
Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 56
Janssen Biotec Enters into Licensing Agreement with MacroGenics 57
Janssen Biotech Enters into Licensing agreement with Tesaro 59
Janssen Biotech Exercises Option for Licensing Agreement with X-Chem 60
ViaCyte Enters into Licensing Agreement with Janssen Biotech 61
Janssen Biotech Exercises Option for Licensing Agreement with Scholar Rock 62
Janssen Biotech to Enter into Licensing Agreement with Alligator Bioscience for ADC-1013 63
Poseida Therapeutics Enters into Licensing Agreement with Janssen Biotech 65
Poseida Therapeutics Enters into Licensing Agreement with Janssen 66
Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 67
Applied Molecular Transport Enters into Licensing Agreement with Janssen Biotech 68
MacroGenics Enters into Licensing Agreement with Janssen Biotech for MGD011 69
Vedanta Biosciences Enters into Licensing Agreement with Janssen Biotech 71
Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech 72
Geron Enters into Licensing Agreement with Janssen Biotech for Imetelstat 74
Modern Biosciences Enters into Licensing Agreement with Janssen Biotech 77
Transposagen BioPharma Enters into Licensing Agreement with Janssen Biotech 78
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 79
Aduro BioTech Enters into Exclusive Licensing Agreement with Janssen Biotech 80
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 81
Amunix Expands Licensing Agreement With Janssen For XTEN Technology 83
CSL Enters Into Licensing Agreement With Janssen For CSL-362 85
Genmab Expands Licensing Agreement With Janssen Biotech 87
Janssen Biotech Exercises Option for Licensing Agreement with OSE Immunotherapeutics 89
Amunix Exercises Option For Licensing Agreement With Janssen Biotech For XTEN Technology 90
Janssen Biotech Exercises Option For Licensing Agreement With Forma Therapeutics 91
Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 93
Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 94
Amunix Enters Into Licensing Agreement With Janssen Biotech For Proprietary XTEN Technology 95
Phenex Pharma Enters Into Licensing Agreement With Janssen Biotech For Retinoid-Acid Receptor-Related Orphan Receptor Gamma t Program 96
Janssen Biotech to Terminate Licensing Agreement with Astellas Pharma for ASP015K 98
Genmab Enters Into Licensing Agreement With Janssen Biotech For Daratumumab 100
ImmuNext Enters Into Licensing Agreement With Janssen Biotech 102
Genmab Enters Into Licensing Agreement With Janssen Biotech For DuoBody Technology 104
Phylogica Enters Into Licensing Agreement With Janssen Biotech For Phylomer Technology 105
Metamark Genetics Enters Into Licensing Agreement With Janssen Biotech 106
Janssen Biotech Enters Into Licensing Agreement With Pharmacyclics For PCI-32765 107
Topivert Enters into Licensing Agreement with RespiVert 109
AVEO Pharma Enters Into Licensing Agreement With Centocor Ortho Biotech 110
Horizon Discovery Enters Into Licensing Agreement With Centocor Ortho Biotech 112
Janssen Biotech Enters Into Option To Acquire Amphivena From Affirmed Therapeutics 113
Janssen Biotech To Acquire Vascular Pharma, Diabetes Drug Developer 115
Centocor Ortho Biotech Acquires RespiVert 116
Janssen Biotech Inc, Key Competitors 118
Janssen Biotech Inc, Key Employees 119
Janssen Biotech Inc, Subsidiaries 120
List Of Figures
List of Figures
Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 8
Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 9
Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 10
Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 11
Janssen Biotech Inc, Medical Devices Deals, 2010 to YTD 2016 13
